View Post

Announcing the new “Dharam Ablashi Research Fund”

In All by Kristin Loomis

The HHV-6 Foundation is pleased to announce the creation of a new $250,000 research fund to honor the work Dharam Ablashi, the co-discoverer of HHV-6. The gift was made possible by a generous donation from a patient family in appreciation of Dharam’s outstanding service to the field of HHV-6 research over four decades. The funds will be used to offer pilot grants of up to $25,000 each to investigators seeking to gather preliminary data before embarking on larger studies.

View Post

HHV-6 identified in 12% of simple and 42% of complex pediatric febrile seizures

In All, CNS Disease, CNS Dysfunction, Epilepsy and Seizures by Kristin Loomis

Australian investigators studied 143 young children with febrile seizures for signs of viral infection and found that HHV-6 was the fifth most common virus after rhinovirus (22%), enterovirus (20%), adenovirus (21%) and influenza (13%). Overall, a virus was found in 71% of cases. Virus found in complex seizures was associated with HHV-6 (42%) or influenza (41%).

View Post

HHV-6, HHV-7 & EBV found in lymphoproliferative disorders of the ocular adnexa

In All, Cancer by Kristin Loomis

Biopsies from patients with 5 types of lymphoproliferative disorders of the ocular adnexa, were found to contain HHV-6 DNA in 9 of 70 (12.9%) samples. While an overall detection rate of 12.9% is significant, HHV-6 was even more prevalent among those with benign lymphoproliferative disorders; HHV-6 was found in 22.7% of those with IgG4-related ophthalmic disease and 28.6% of those with orbital reactive lymphoid hyperplasia.

View Post

Rapid point-of-care system screens for 14 encephalitis pathogens in one hour!

In All, CNS Disease, CNS Dysfunction, Encephalitis & Encephalopathy by Kristin Loomis

A new point-of-care assay from bioMérieux can simultaneously and rapidly detect 14 pathogens typically found in encephalitis. The machine is designed to be at the clinic or in the emergency room and can be operated by unskilled technicians. In a study of 1,560 immunocompetent patient samples, a total of 1.35% were positive for HHV-6, or about twice the expected rate of 0.8% found with the inherited chromosomally integrated HHV-6.

View Post

HHV-6 found to cause 35% of CNS infections in allo-HSCT transplantation

In All, CNS Disease, Transplant Complications by Kristin Loomis

A retrospective analysis out of the Tokyo Metropolitan Cancer and Infectious Diseases Center reviewed 353 consecutive adult allogeneic hematopoietic stem cell transplant (allo-HSCT) cases and identified 17 cases of CNS infection post-transplant. As determined by PCR on cerebrospinal fluid, HHV-6 was found to be the causative agent in 6 cases, or 1.7% of all transplants.

View Post

New data on HHV-6B levels in CD134+ CD4+ cells

In All, Transplant Complications by Kristin Loomis

A group from the University of Minnesota studied the T cells of umbilical cord blood transplant patients and found that CD4+ T lymphocytes co-expressing CD134 contained more than twice the level of HHV-6B than cells without CD134 expression. Surprisingly, almost 70% of the CD134 negative cells contained HHV-6.

View Post

HHV-6B saliva viral loads peak 3-7 months after primary infection

In All, Epidemiology by Kristin Loomis

A new study on HHV-6B shedding in saliva during and after exanthema subitum found that peak detection rates and viral loads occurred during the convalescent period, between 3 to 7 months post-illness. Detection rates were lower in adults than in children suggesting that siblings may be more likely to transmit the virus than parents.

View Post

Low dose emetine shows promise as a herpesvirus antiviral

In All, Latest Scientific News, Treatments - Antiviral by Kristin Loomis

Investigators at Johns Hopkins have determined that emetine, an older drug used to treat dysentery as well as to induce vomiting, is also effective against cytomegalovirus (CMV/HHV-5). Not only was emetine effective at an extremely low dose, it demonstrated a synergistic effect when combined with ganciclovir in a mouse model of CMV infection and it worked at a much earlier stage of viral replication than the drugs currently in use.